维普期刊资源整合服务平台（V6.5）

42篇 您的检索式：作者名="Callaghan JT"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Olanzapine- Pharmacokinetic and pharmacodyna- mic profile显示文摘	Callaghan JT Bergstrom RF Ptak LR	1999	Clin Pharmacokinet1999，37，3：	1
2	Olanzapine: pharmacokinetic and pharmacodynamic profile 显示文摘	Callaghan JT Bergstrom RF Ptak LR	1999	Drug Disposition1999，37，3：	1
3	The conduct of in vitro and in vivo drug-drug interaction studies:a pharma perspective显示文摘	Bjornsson TD Callaghan JT Einolf HJ		0，，05：	1
4	Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing显示文摘	Hershfield MS Callaghan JT Tassaneeyakul W	2013	Clin Pharmacol Ther2013，93，2：	1
5	Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing显示文摘	Hershfield MS Callaghan JT Tassaneeyakul W	2013	Clin Pharmacol Ther2013，93，2：	1
6	The conduct of in vitro and in vivo drug-drug interaction studies:a Pharmaceutical Research and Manufacturers of America(Ph RMA)perspective显示文摘	Bjornsson TD Callaghan JT Einolf HJ	2003	Drug Metab Dispos2003，31，7：	1
7	Concise review:limbal epithelial stem cell therapy:controversies and challenges显示文摘	O'Callaghan AR1 Daniels JT	2011	Stem Cells2011，29，12：	1
8	Clinical Pharmaeogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing显示文摘	Hershfield MS Callaghan JT Tassaneeyakul W	2013	Clin Pharmacol Ther2013，93，2：	1
9	Theconduct of in vitro and in vivo drug-drug interactionstudies:a PhRMA perspective显示文摘	Bjornsson TD Callaghan JT Einolf HJ	2003	J Clin Pharma-col2003，43，5：	1
10	Concise review : limbal epithelial stem cell therapy : controversies and chall' enges显示文摘	O’Callaghan AR Daniels JT	2011	Stem Cells2011，29，12：	1
11	The conduct of in vitro and in vivo drug - drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective 显示文摘	Bjornsson TD Callaghan JT Einolf HJ	2003	Drug Metab Dispos2003，31，：	1
12	Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing 显示文摘	Hershfield MS Callaghan JT Tassaneeyakul W	2013	Clin Pharmacol Ther2013，93，2：	1
13	Olanzapine : pharmacokinetic and pharmacodynamic profile 显示文摘	Callaghan JT Bergstrom RF Ptak LR	1999	Clin Pharmacokinet1999，37，3：	1
14	Olanzapine: pharmacokinetic and pharmacodynamic profile显示文摘	Callaghan JT Bergstrom RF Ptak LR	1999	Drug Disposit1999，37，3：	1
15	The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective显示文摘	Bjornsson TD Callaghan JT Einolf HJ	2003	Drug Metab Dispos2003，31，7：	1
16	The con- duct of in vitro and in vivo drug-drug interaction studies : a Phar- maceutical Research and Manufacturers of America(PhRMA) per- spective显示文摘	BJOMSSON TD CALLAGHAN JT EINOLF HJ	2003	Drug Metab Dispos2003，31，7：	1
17	Abserption studies of the H2-bloeker nizatidine显示文摘	Bergstrom RF Callaghan JT	1987	Clin Pharmacol Ther1987，42，5：	1
18	Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion显示文摘	Callaghan JT Bergstrom RF	1990	Clin Pharmacol Ther1990，47，4：	1
19	Clinical Pharmacogenetics Implementation Consortium guidelines for hu?man leukocyte antigen-B genotype and allopurinol dosing显示文摘	Hershfield MS Callaghan JT Tassaneeyakul W	2013	Clin Pharmacol Ther2013，93，：	1
20	Absorption studies of the H2 - blocker nizatidine 显示文摘	Knadler MP Bergstrom RF Callaghan JT	1987	Clin Pharmacol Ther1987，42，5：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示